Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
One year of adjuvant trastuzumab is considered the standard treatment for patients with HER2 positive breast cancer. However, a shorter duration of trastuzumab may be associated with reduced costs and side effects. Results from randomized trials with diverse non-inferiority margins comparing one yea...
Shranjeno v:
| Principais autores: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2020-12-01
|
| Serija: | Breast |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S0960977620301946 |
| Oznake: |
Brez oznak, prvi označite!
|